{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:47:22Z","timestamp":1791946042596,"version":"4.3.4"},"reference-count":117,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Vitiligo is a chronic autoimmune dermatosis of which the pathogenesis remains scarcely known. A wide variety of clinical studies have been proposed to investigate the immune mediators which have shown the most recurrency. However, such trials have produced controversial results. The aim of this review is to summarize the main factors involved in the pathogenesis of vitiligo, the latest findings regarding the cytokines involved and to evaluate the treatments based on the use of biological drugs in order to stop disease progression and achieve repigmentation. According to the results, the most recurrent studies dealt with inhibitors of IFN-gamma and TNF-alpha. It is possible that, given the great deal of cytokines involved in the lesion formation process of vitiligo, other biologics could be developed in the future to be used as adjuvants and\/or to entirely replace the treatments that have proven to be unsatisfactory so far.<\/jats:p>","DOI":"10.3390\/ijms222111429","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:06:16Z","timestamp":1635113176000},"page":"11429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Role of Cytokines in Vitiligo: Pathogenesis and Possible Targets for Old and New Treatments"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2142-5054","authenticated-orcid":false,"given":"Paolo","family":"Custurone","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5457-6246","authenticated-orcid":false,"given":"Luca","family":"Di Bartolomeo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Irrera","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pharmacology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3515-8441","authenticated-orcid":false,"given":"Francesco","family":"Borgia","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Altavilla","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pharmacology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bitto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pharmacology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4187-2265","authenticated-orcid":false,"given":"Giovanni","family":"Pallio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pharmacology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Squadrito","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Pharmacology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3787-5145","authenticated-orcid":false,"given":"Mario","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Via C. Valeria, Gazzi, 98125 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/bjd.12652","article-title":"Classification of segmental vitiligo on the trunk","volume":"170","author":"Bosma","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fendo.2017.00290","article-title":"Vitiligo and Autoimmune Thyroid Disorders","volume":"8","author":"Baldini","year":"2017","journal-title":"Front. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"New discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","first-page":"167","article-title":"Update on the genetics characterization of vitiligo","volume":"5","year":"2011","journal-title":"Int. J. Health Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0749.2005.00279.x","article-title":"HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset","volume":"19","author":"Fain","year":"2006","journal-title":"Pigment. Cell Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Philips, M.-A., Kingo, K., Karelson, M., R\u00e4tsep, R., Aunin, E., Reimann, E., Reemann, P., Porosaar, O., Vikes\u00e5, J., and Nielsen, F.C. (2010). Promoter polymorphism-119C\/G in MYG1 (C12orf10) gene is related to vitiligo susceptibility and Arg4Gln affects mitochondrial entrance of Myg1. BMC Med. Genet., 11.","DOI":"10.1186\/1471-2350-11-56"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","article-title":"Genetics of Vitiligo","volume":"35","author":"Spritz","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/1346-8138.13886","article-title":"Altered expression of four miRNA (miR-1238-3p, miR-202-3p, miR-630 and miR-766-3p) and their potential targets in peripheral blood from vitiligo patients","volume":"44","author":"Shang","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jdermsci.2020.10.014","article-title":"Serum levels of miRNA-21-5p in vitiligo patients and effects of miRNA-21-5p on SOX5, beta-catenin, CDK2 and MITF protein expression in normal human melanocytes","volume":"101","author":"Aguennouz","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ceca.2016.04.002","article-title":"Oxidative stress, microRNAs and cytosolic calcium homeostasis","volume":"60","author":"Magenta","year":"2016","journal-title":"Cell Calcium"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"631927","DOI":"10.1155\/2015\/631927","article-title":"Oxidative Stress and Immune System in Vitiligo and Thyroid Diseases","volume":"2015","author":"Colucci","year":"2015","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.12659\/MSM.914898","article-title":"Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity","volume":"25","author":"Wang","year":"2019","journal-title":"Med. Sci. Monit."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbrc.2007.05.218","article-title":"Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: More evidence for oxidative stress in vitiligo","volume":"360","author":"Schallreuter","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1034\/j.1600-0749.2000.130404.x","article-title":"MITF: A stream flowing for pigment cells","volume":"13","author":"Tachibana","year":"2000","journal-title":"Pigment. Cell Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/jid.2014.65","article-title":"Melanocytes as instigators and victims of oxidative stress","volume":"134","author":"Denat","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/jid.2014.152","article-title":"Impaired activation of the Nrf2-ARE signaling pathway undermines H2O2-induced oxidative stress response: A possible mechanism for melanocyte degeneration in vitiligo","volume":"134","author":"Jian","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-120-3-199402010-00009","article-title":"Nitric oxide: A physiologic messenger","volume":"120","author":"Lowenstein","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archderm.1996.03890320037005","article-title":"From bedside to the bench and back. Nitric oxide and cutis","volume":"132","author":"Qureshi","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Vaccaro, M., Irrera, N., Cutroneo, G., Rizzo, G., Vaccaro, F., Anastasi, G.P., Borgia, F., Cannav\u00f2, S.P., Altavilla, D., and Squadrito, F. (2017). Differential Expression of Nitric Oxide Synthase Isoforms nNOS and iNOS in Patients with Non-Segmental Generalized Vitiligo. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122533"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00403-017-1746-z","article-title":"Oxidation products are increased in patients affected by non-segmental generalized vitiligo","volume":"309","author":"Vaccaro","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.prp.2016.12.019","article-title":"Reduced immunohistochemical expression of adhesion molecules in vitiligo skin biopsies","volume":"213","author":"Jung","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jdermsci.2013.04.005","article-title":"Role of alpha5beta1 integrin and MIA (melanoma inhibitory activity) in the pathogenesis of vitiligo","volume":"71","author":"Bordignon","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111615","DOI":"10.1016\/j.yexcr.2019.111615","article-title":"miR-9 regulates melanocytes adhesion and migration during vitiligo repigmentation induced by UVB treatment","volume":"384","author":"Su","year":"2019","journal-title":"Exp. Cell Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/exd.14157","article-title":"Decreased suppression of CD8+ and CD4+ T cells by peripheral regulatory T cells in generalized vitiligo due to reduced NFATC1 and FOXP3 proteins","volume":"29","author":"Giri","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"613056","DOI":"10.3389\/fimmu.2021.613056","article-title":"Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective","volume":"12","author":"Boniface","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaci.2019.10.036","article-title":"Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo","volume":"145","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1073\/pnas.1222808110","article-title":"NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1\u03b2 processing via the NLRP1 inflammasome","volume":"110","author":"Levandowski","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: An overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Tigges","year":"2003","journal-title":"Lab. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/jid.2011.377","article-title":"IFN-\u03b3, IL-21, and IL-10 co-expression in evolving autoimmune vitiligo lesions of Smyth line chickens","volume":"132","author":"Shi","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, S., Zhou, M., Lin, F., Liu, D., Hong, W., Lu, L., Zhu, Y., and Xu, A. (2014). Interferon-\u03b3 induces senescence in normal human melanocytes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093232"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","article-title":"Cross-regulation of signaling pathways by interferon-gamma: Implications for immune responses and autoimmune diseases","volume":"31","author":"Hu","year":"2009","journal-title":"Immunity"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Expression in Vitiligo","volume":"25","author":"Tawfik","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4049\/jimmunol.0903412","article-title":"Cutting edge: The Th1 response inhibits the generation of peripheral regulatory T cells","volume":"184","author":"Caretto","year":"2010","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/CCID.S210106","article-title":"Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo","volume":"12","author":"Samaka","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40257-013-0039-3","article-title":"The role of tumor necrosis factor-\u03b1 in the pathogenesis of vitiligo","volume":"14","year":"2013","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155432","DOI":"10.1016\/j.cyto.2021.155432","article-title":"Tumor Necrosis Factor-alpha affects melanocyte survival and melanin synthesis via multiple pathways in vitiligo","volume":"140","author":"Singh","year":"2021","journal-title":"Cytokine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2011.09.017","article-title":"TNF\u03b1: Activator or inhibitor of regulatory T cells?","volume":"79","author":"Biton","year":"2012","journal-title":"Joint Bone Spine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/ced.12464","article-title":"Interleukin-33 affects cytokine production by keratinocytes in vitiligo","volume":"40","author":"Li","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00403-016-1675-2","article-title":"IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo","volume":"308","author":"Vaccaro","year":"2016","journal-title":"Arch. Dermatol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjd.12691","article-title":"Inflammasome activation and vitiligo\/nonsegmental vitiligo progression","volume":"170","author":"Marie","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cyto.2016.12.014","article-title":"Increased systemic and epidermal levels of IL-17A and IL-1\u03b2 promotes progression of non-segmental vitiligo","volume":"91","author":"Bhardwaj","year":"2017","journal-title":"Cytokine"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Laddha, N.C., Dwivedi, M., Mansuri, M.S., Singh, M., Patel, H.H., Agarwal, N., Shah, A.M., and Begum, R. (2014). Association of neuropeptide Y (NPY), interleukin-1B (IL1B) genetic variants and correlation of IL1B transcript levels with vitiligo susceptibility. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107020"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/ijc.25182","article-title":"Interleukins 1alpha and 1beta secreted by some melanoma cell lines strongly reduce expression of MITF-M and melanocyte differentiation antigens","volume":"127","author":"Kholmanskikh","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-\u03b1) in vitiligo-New insight into pathogenesis of disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/13685538.2020.1806814","article-title":"Levels of TNF-\u03b1, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo","volume":"23","author":"Baysak","year":"2020","journal-title":"Aging Male"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00403-012-1277-6","article-title":"Subtoxic levels hydrogen peroxide-induced expression of interleukin-6 by epidermal melanocytes","volume":"304","author":"Yao","year":"2012","journal-title":"Arch. Dermatol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1038\/jid.2012.328","article-title":"Activation of the unfolded protein response in vitiligo: The missing link?","volume":"132","author":"Passeron","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_56","first-page":"1","article-title":"Investigation of the Role of Interleukin 6 in Vitiligo Pathogenesis","volume":"30","author":"Singh","year":"2020","journal-title":"Immunol. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2230.2010.03972.x","article-title":"Role of interleukin-17 in the pathogenesis of vitiligo","volume":"36","author":"Bassiouny","year":"2011","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jdermsci.2018.12.005","article-title":"Circulating CCL20: A potential biomarker for active vitiligo together with the number of Th1\/17 cells","volume":"93","author":"Zhang","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/pcmr.12355","article-title":"Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 are correlated with human non-segmental vitiligo development","volume":"28","author":"Zhou","year":"2015","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","article-title":"Interleukin-17 family members and inflammation","volume":"21","author":"Kolls","year":"2004","journal-title":"Immunity"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1684\/ejd.2013.2023","article-title":"Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case-controlled study on eighty-four patients","volume":"23","author":"Elela","year":"2013","journal-title":"Eur. J. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109161","DOI":"10.18632\/oncotarget.22644","article-title":"Interleukin-22 participates in the inflammatory process of vitiligo","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/ijd.12392","article-title":"Increased serum levels of interleukin-23 circulating in patients with non-segmental generalized vitiligo","volume":"54","author":"Vaccaro","year":"2015","journal-title":"Int. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.4103\/0019-5154.169136","article-title":"Plasma Levels of Interleukin-17, Interleukin-23, and Transforming Growth Factor-\u03b2 in Sudanese Patients with Vitiligo: A Case-Control Study","volume":"60","author":"Osman","year":"2015","journal-title":"Indian J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"618897","DOI":"10.3389\/fimmu.2020.618897","article-title":"Pathophysiology of Skin Resident Memory T Cells","volume":"11","author":"Tokura","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on Vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(00)01034-5","article-title":"Therapeutic monoclonal antibodies","volume":"355","author":"Breedveld","year":"2000","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3899\/jrheum.120253","article-title":"Ustekinumab for psoriasis and psoriatic arthritis","volume":"89","author":"Goldminz","year":"2012","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jdcr.2017.07.009","article-title":"Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata","volume":"3","author":"Elkady","year":"2017","journal-title":"JAAD Case Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"Bagny","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/fcp.12558","article-title":"Drug-induced vitiligo: A case\/non-case study in Vigibase\u00ae, the WHO pharmacovigilance database","volume":"34","author":"Anthony","year":"2020","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_73","first-page":"301","article-title":"New-onset vitiligo as an unusual cutaneous reaction under ustekinumab therapy in patients with psoriatic arthritis","volume":"45","author":"Gedikli","year":"2020","journal-title":"Acta Reumatol. Port."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"omz134","DOI":"10.1093\/omcr\/omz134","article-title":"Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris","volume":"2020","author":"Palazzo","year":"2020","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s40261-020-00964-w","article-title":"New-Onset Vitiligo during Treatment with Secukinumab: Report of Two Cases and Review of the Literature","volume":"40","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2021.03.008","article-title":"Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab","volume":"11","author":"Raimondo","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/idoj.IDOJ_53_19","article-title":"Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris","volume":"11","author":"Bonifaz","year":"2020","journal-title":"Indian Dermatol. Online J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e13347","DOI":"10.1111\/dth.13347","article-title":"New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab","volume":"33","author":"Phan","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000324619","article-title":"Vitiligo during Treatment of Crohn\u2019s Disease with Adalimumab: Adverse Effect or Co-Occurrence?","volume":"3","author":"Posada","year":"2011","journal-title":"Case Rep. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5021\/ad.2015.27.5.620","article-title":"Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?","volume":"27","author":"Jung","year":"2015","journal-title":"Ann. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e12917","DOI":"10.1111\/dth.12917","article-title":"Vitiligo in a patient receiving infliximab for chronic plaque psoriasis","volume":"32","author":"Lu","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"826","DOI":"10.5021\/ad.2017.29.6.826","article-title":"A Type II Segmental Vitiligo Developed under Infliximab Treatment for Ulcerative Colitis","volume":"29","author":"Ryu","year":"2017","journal-title":"Ann. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/imj.13498","article-title":"New onset vitiligo following commencement of infliximab in Crohn disease","volume":"47","author":"Luber","year":"2017","journal-title":"Intern. Med. J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1590\/abd1806-4841.20142887","article-title":"Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report","volume":"89","author":"Carvalho","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_86","first-page":"217","article-title":"New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ajg.2011.03.001","article-title":"Vitiligo in a patient receiving infliximab for refractory ulcerative colitis","volume":"12","author":"Ismail","year":"2011","journal-title":"Arab J. Gastroenterol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000081494","article-title":"Infliximab-induced vitiligo","volume":"210","author":"Marras","year":"2005","journal-title":"Dermatology"},{"key":"ref_89","first-page":"534","article-title":"Treatment of generalized vitiligo with anti-TNF-\u03b1 Agents","volume":"11","author":"Alghamdi","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/bjd.14016","article-title":"Tumour necrosis factor-\u03b1 inhibition can stabilize disease in progressive vitiligo","volume":"173","author":"Webb","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/15569527.2011.560913","article-title":"Tumor necrosis factor-\u03b1 in vitiligo: Direct correlation between tissue levels and clinical parameters","volume":"30","author":"Kim","year":"2011","journal-title":"Cutan. Ocul. Toxicol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2165\/1153424-S0-000000000-00000","article-title":"A patient with psoriasis and vitiligo treated with etanercept","volume":"11","author":"Campanati","year":"2010","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000102044","article-title":"Etanercept in the treatment of vitiligo","volume":"215","author":"Rigopoulos","year":"2007","journal-title":"Dermatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ced.13290","article-title":"Oral tofacitinib: A promising treatment in atopic dermatitis, alopecia areata and vitiligo","volume":"42","author":"Vu","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.abd.2019.08.032","article-title":"Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation","volume":"95","author":"Komnitski","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5152\/eurjrheum.2020.20007","article-title":"Tofacitinib-induced remission simultaneously in arthritis and vitiligo","volume":"8","author":"Scheinberg","year":"2021","journal-title":"Eur. J. Rheumatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ccr3.2759","article-title":"Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis","volume":"8","author":"Tajalli","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3889\/oamjms.2018.042","article-title":"Micro\u2014Focused Phototherapy Associated to Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo","volume":"6","author":"Gianfaldoni","year":"2018","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/pde.14159","article-title":"Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child","volume":"37","author":"Olamiju","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"omw027","DOI":"10.1093\/omcr\/omw027","article-title":"Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy","volume":"2016","author":"Nadesalingam","year":"2016","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/jdv.15117","article-title":"Vitiligo remitting with tocilizumab","volume":"33","author":"Bunker","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdin.2020.10.007","article-title":"A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy","volume":"2","author":"Sachdeva","year":"2020","journal-title":"JAAD Int."},{"key":"ref_111","first-page":"1","article-title":"Inhibition of IFN-gamma as a method of treatment of various autoimmune diseases, including skin diseases","volume":"56","author":"Skurkovich","year":"2006","journal-title":"Ernst Schering Res. Found. Workshop"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/jid.2011.463","article-title":"A mouse model of vitiligo with focused epidermal depigmentation requires IFN-\u03b3 for autoreactive CD8+ T-cell accumulation in the skin","volume":"132","author":"Harris","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jid.2018.10.032","article-title":"Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo","volume":"139","author":"Richmond","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/ni.2745","article-title":"Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells","volume":"14","author":"Skon","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/s41598-018-19407-w","article-title":"PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin","volume":"8","author":"Miao","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/jim-2020-001390","article-title":"Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo","volume":"69","author":"Zhang","year":"2021","journal-title":"J. Investig. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:21:31Z","timestamp":1760167291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/21\/11429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":117,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijms222111429"],"URL":"https:\/\/doi.org\/10.3390\/ijms222111429","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}